Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study

被引：10

作者：

Fasching, P. A. ^{[1
]}

Fehm, T. ^{[2
,39
]}

Kellner, S. ^{[3
]}

de Waal, J. ^{[3
]}

Rezal, M. ^{[4
]}

Baler, B. ^{[3
]}

Baake, G. ^{[5
]}

Kolberg, H. -C ^{[6
]}

Guggenberger, M. ^{[7
]}

Warm, N. ^{[3
,8
,9
]}

Harbeck, N. ^{[29
]}

Wuerstlein, R. ^{[10
]}

Deuker, J. -U ^{[11
,21
]}

Dall, P. ^{[12
,31
]}

Richter, B. ^{[32
]}

Wachsmann, G. ^{[13
]}

Brucker, C. ^{[14
]}

Siebers, J. W. ^{[15
]}

Fersis, N. ^{[16
]}

Kuhn, T. ^{[17
]}

Wolf, C. ^{[18
]}

Vollert, H. -W ^{[19
]}

Breitbach, G. -P ^{[20
,22
]}

Janni, W. ^{[21
]}

Landthaler, R. ^{[22
]}

Kohls, A. ^{[23
,33
]}

Rezek, D. ^{[24
,28
]}

Nosslet, T. ^{[25
,27
]}

Fischer, G. ^{[26
]}

Henschen, S. ^{[28
]}

Praetz, T. ^{[29
]}

Heyl, V. ^{[35
]}

Kuehn, T. ^{[30
,32
]}

Krauss, T. ^{[31
]}

Thomssen, C. ^{[32
]}

Kuemmel, S. ^{[33
]}

Hohn, A. ^{[34
]}

Tesch, H. ^{[35
]}

Mundhenke, C. ^{[31
]}

Hein, A. ^{[1
,33
]}

Rauh, C. ^{[1
]}

Bayer, C. M. ^{[1
]}

Jacob, A. ^{[37
]}

Schmidt, K. ^{[37
]}

Belleville, E. ^{[31
]}

Hadji, P. ^{[38
]}

Wallwiener, D. ^{[39
]}

Grischice, E. -M ^{[36
,39
]}

Beckmann, M. W. ^{[1
]}

Brucker, S. Y.

机构：

[1] Univ Erlangen Nurnberg, Univ Brustzentrum Franken, Frauenklin, Comprehens Canc Ctr Erlangen EMN,Univ Klinikum Er, D-91054 Erlangen, Germany

[2] Univ Frauenklin Dusseldorf, Dusseldorf, Germany

[3] Frauenklin Klinikum Dachau, Dachau, Germany

[4] Luisenkrankenhaus Dusseldorf, Dusseldorf, Germany

[5] Klinikum Pinneberg, Pinneberg, Germany

[6] Marienhosp Bottrop, Bottrop, Germany

[7] Klinikum Tuttlingen, Tuttlingen, Germany

[8] Univ Frauenklin Koln, Brustzentrum, Cologne, Germany

[9] Klinken Stadt Koln gGmbH Holweide, Brustzentrum, Cologne, Germany

[10] Univ Munich, Brustzentrum, Frauenkliniken Grosshadern & Maistr Innenstad, Munich, Germany

[11] Klinikum Luneburg, Frauenklin, Luneburg, Germany

[12] Elblandkliniken Meissen Radebeul Standort Radebeu, Radebeul, Germany

[13] Kreiskrankenhaus Boblingen, Boblingen, Germany

[14] Paracelsus Med Privatuniv, Univ Klin Frauenheilkunde, Nurnberg, Germany

[15] St Josefklin Offenburg, Frauenklin, Offenburg, Germany

[16] Klinikum Bayreuth GmbH, Comprehens Canc Ctr Erlangen EMN, Frauenklin, Bayreuth, Germany

[17] Karl Olga Krankenhaus, Stuttgart, Germany

[18] Med Zentrurn Ulm, Ulm, Germany

[19] Klinikum Friedrichshafen, Friedrichshafen, Germany

[20] Stadt Klinikum Neunkirchen Gynakol & Geburtshilfe, Neunkirchen, Germany

[21] Univ Ulm Klinikum, Frauenklin, Ulm, Germany

[22] Gynakol Praxis Kreisklin, Krumbach, Germany

[23] Evangel Krankenhaus Ludwigsfelde Teltow, Ludwigsfelde, Germany

[24] Marien Hosp Wesel, Wesel, Germany

[25] Frauenklin Kreiskrankenhaus Hameln, Hameln, Germany

[26] Landkreis Mittweida Krankenhaus gGmbH, Mittweida, Germany

[27] Johanniter Krankenhaus Genthin Stendal gGmbH, Stendal, Germany

[28] Praxis Dr Praetz, Bad Mergenlheim, Germany

[29] Asklepios Paulinen Klin Wiesbaden, Wiesbaden, Germany

[30] Stadt Kliniken Esslingen aN, Frauenklin, Esslingen, Germany

[31] Frauenklin Lippe, Lippe, Germany

[32] Univ Klin Halle Wittenberg, Frauenklin, Halle, Germany

[33] Evang Huyssens Stiftung Knappschaft GmbH, Kliniken Essen Mitte, Brustzentrum, Essen, Germany

[34] Kreiskrankenhaus Rendsburg, Rendsburg, Germany

[35] Onkol Bethanien, Frankfurt, Germany

[36] Univ Klinikum Schleswig Holstein Campus Kiel, Kiel, Germany

[37] Novartis Pharma GmbH, Nurnberg, Germany

[38] Krankenhaus NW Frankfurt, Klin Gynakol & Gebursthilfe, Frankfurt, Germany

[39] Univ Frauenklin Tubingen, Tubingen, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2014年 / 74卷 / 12期

关键词：

breast cancer; aromatase inhibitor; compliance; endocrine therapy; ADJUVANT ENDOCRINE THERAPY; PATIENTS ANASTROZOLE COMPLIANCE; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; PACT PROGRAM; WOMEN; EXEMESTANE; COMBINATION; ADHERENCE;

D O I：

10.1055/s-0034-1383401

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.

引用

页码：1137 / 1143

页数：7

共 50 条

[21] Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer
Schickli, M. Alexandra
Berger, Michael J.
Lustberg, Maryam
Palettas, Marilly
Vargo, Craig A.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1374 - 1380
[22] The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
Ciruelos, Eva
Pascual, Tomas
Arroyo Vozmediano, Maria Luisa
Blanco, Marta
Manso, Luis
Parrilla, Lucia
Munoz, Cesar
Vega, Estela
Jackelin Calderon, Monica
Sancho, Blanca
Cortes-Funes, Hernan
BREAST, 2014, 23 (03) : 201 - 208
[23] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
Hiroji Iwata
Breast Cancer, 2011, 18 : 92 - 97
[24] Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy
Sulaica, Elisabeth
Han, Tiffany
Wang, Weiqun
Bhat, Raksha
Trivedi, Meghana V.
Niravath, Polly
BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 203 - 210
[25] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
Yi-Dan Yan
Jie Fu
Zhi-Chun Gu
Jin-Song Lu
Ying-Jie Su
Hou-Wen Lin
International Journal of Clinical Pharmacy, 2023, 45 : 184 - 190
[26] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
Delea, Thomas E.
Karnon, Jon
Sofrygin, Oleg
Thomas, Simu K.
Papo, Natalie L.
Barghout, Victoria
CLINICAL BREAST CANCER, 2007, 7 (08) : 608 - 618
[27] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
Iwata, Hiroji
BREAST CANCER, 2011, 18 (02) : 92 - 97
[28] Fulvestrant in management of hormone receptor-positive metastatic breast cancer
Shafaee, Maryam Nemati
Ellis, Matthew James
FUTURE ONCOLOGY, 2018, 14 (18) : 1789 - 1800
[29] Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer
Bracken-Clarke, Dara B.
Lucas, Mairi W.
Higgins, Michaela J.
BREAST CARE, 2017, 12 (03) : 138 - 144
[30] Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients
Nabieva, N.
Kellner, S.
Fehm, T.
Haebrle, L.
de Waal, J.
Rezai, M.
Baier, B.
Baake, G.
Kolberg, H. -C.
Guggenberger, M.
Warm, M.
Harbeck, N.
Wuerstlein, R.
Deuker, J. -U.
Dall, P.
Richter, B.
Wachsmann, G.
Brucker, C.
Siebers, J. W.
Fersis, N.
Kuhn, T.
Wolf, C.
Vollert, H. -W.
Breitbach, G. -P.
Janni, W.
Landthaler, R.
Kohls, A.
Rezek, D.
Noesselt, T.
Fischer, G.
Henschen, S.
Praetz, T.
Heyl, V.
Kuehn, T.
Krauss, T.
Thomssen, C.
Hohn, A.
Tesch, H.
Mundhenke, C.
Hein, A.
Rauh, C.
Bayer, C. M.
Jacob, A.
Schmidt, K.
Belleville, E.
Brucker, S. Y.
Kuemmel, S.
Beckmann, M. W.
Wallwiener, D.
Hadji, P.
ANNALS OF ONCOLOGY, 2018, 29 (01) : 186 - 192

← 1 2 3 4 5 →